IA
ICPT

IFP Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

IFP Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300
Closed -$25K – 4064
2018
Q2 		$25K Buy
+300
New +$22K ﹤0.01% 2346

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
EULAV Asset Management Sarasota, Florida $3.12B AUM 13.38% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IFP Advisors's ICPT Position: Q3 2021 in Review

IFP Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2021, closing a stake of 532 shares — an estimated $12K sold.

IFP Advisors first reported a position in ICPT in Q4 2015 and held it in 22 quarters. The position peaked at $372K in Q3 2018. 139 funds tracked by Wall St. Rank hold ICPT as of Q3 2021.

  • IFP Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • IFP Advisors sold 532 Intercept Pharmaceuticals, Inc. shares in Q3 2021, an estimated $12K.
  • IFP Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2015 and held it in 22 quarters.
  • IFP Advisors's Intercept Pharmaceuticals, Inc. position peaked at $372K in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2021.

Based on IFP Advisors's 13F filing for Q3 2021, filed 6 Oct 2021.